Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

UFS receives R3,284 million to research biosafety of genetically modified crops
2009-03-17

A testing facility at the University of the Free State (UFS), which is the only one of its kind in South Africa and a leader in its field in Africa, has received a grant of R3,284 million from the South African National Biodiversity Institute (SANBI) to do research on the biosafety of genetically modified crops in South Africa.

Prof. Chris Viljoen of the Genetically Modified Organisms (GMO) Testing Facility at the UFS says the grant forms part of a collaborative agreement between South Africa and Norway on the biosafety of GMOs.

The grant also makes provision for two M.Sc. bursaries as well as a regional biosafety workshop.

The research will focus on gene flow between genetically modified (GM) maize and non-GM maize and the potential impact thereof on the development of insect resistance.

Prof. Viljoen, who is head of Human Molecular Biology in the Department of Haematology and Cell Biology, says it is an honour to be selected to take part in the project and is groundbreaking in terms of GM maize on the environment. The project was initiated in 2009 and will run until the end of 2010.

The multi-institutional research include partners from the UFS, research groups from the University of North-West, the University of Fort Hare as well as SANBI and GenØk, the Norwegian centre for Gene Ecology. The GMO Testing Facility at the UFS was established in 2003 to perform routine GM detection for grain and food products in South Africa. The activities also include research into GM detection and biosafety of GM crops.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za
17 March 2009
 
 
Prof. Chris Viljoen of the Genetically Modified Organisms (GMO) Testing Facility at the UFS.
Photo: Supplied

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept